Professor Sara Hurvitz (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA) discusses her presentation at the San Antonio Breast Cancer Symposium 2021 on the aims, efficacy and safety findings of the TRINITI-1 study.
Questions
1. What are the major unmet needs in the treatment of women with HR+, HER2− breast cancer? 00:12-02:06
2. What were the aims, efficacy and safety findings of the TRINITI-1 study? 02:06-05:22
3. What will be the clinical impact of these findings? 05:22-06:06
Speaker Disclosure: Sara Hurvitz has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021
